Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 31;17(11):1858.
doi: 10.3390/cancers17111858.

Lipid Metabolism Reprogramming in Tumor-Associated Macrophages Modulates Their Function in Primary Liver Cancers

Affiliations
Review

Lipid Metabolism Reprogramming in Tumor-Associated Macrophages Modulates Their Function in Primary Liver Cancers

Barbara Oliviero et al. Cancers (Basel). .

Abstract

Lipids are a complex class of biomolecules with pivotal roles in the onset, progression, and maintenance of cancers. Lipids, derived from the tumor microenvironment (TME) or synthesized by cancer cells themselves, govern a large variety of pro-tumorigenic functions. In recent years, lipid metabolism and the reprogramming of liver cancer cells have received increasing attention, revealing that altered regulation of diverse lipid species, including triacylglycerols, phospholipids, sphingolipids, ceramides, fatty acids, and cholesterol, actively contributes to the initiation and progression of primary liver cancer. Lipid metabolic reprogramming also modifies the TME by influencing the recruitment, activation, and function of immune cells. Tumor-associated macrophages (TAM) are essential components of TME that sustain cancer growth, promoting invasion and mediating immune evasion. Macrophage polarization toward a tumor-supportive phenotype is associated with metabolic reprogramming. Indeed, lipid accumulation and enhanced fatty acid oxidation in TAM contribute to polarization to a M2 phenotype. In this review, we examine lipid metabolism in hepatocellular carcinoma and cholangiocarcinoma, focusing on TAM lipid metabolic reprogramming.

Keywords: cholangiocarcinoma; hepatocellular carcinoma; immunosuppression; lipids; macrophages; metabolism; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Lipid content is highly deregulated in primary liver cancer. The figure summarizes lipid alterations in HCC and iCCA as discussed in the text. BA: bile acids; Cer: ceramides; CHOL: cholesterol; FA: fatty acids; GPL: glycerophospholipids; LPCs: lyso-phosphatidylcholines; MUFA: mono-unsaturated fatty acids; MUFA-PCs: mono-unsaturated fatty acids phosphatidylcholines; PCs: phosphatidylcholines; PUFA: poly-unsaturated fatty acids; S1P: sphingosine -1 phosphate; SFA: saturated fatty acids; SM: sphingomyelins; SPL: sphingolipids; ST: sterols. This presentation was created by BioRender (version 201).
Figure 2
Figure 2
The lipid content and lipid metabolism of tumor cells are profoundly altered in primary liver cancers, perturbing the tumor microenvironment. Recent advances in single-cell and spatial technologies have revealed that macrophages within the tumor microenvironment of primary liver cancers constitute a remarkably heterogeneous population, characterized by diverse phenotypes, multifaceted functions, and a high degree of plasticity. Macrophages are influenced by the exchange of lipids derived from tumor cells, which ultimately promote immunosuppression and tumor progression. This presentation was created by BioRender (version 201).

References

    1. Villanueva A. Hepatocellular Carcinoma. N. Engl. J. Med. 2019;380:1450–1462. doi: 10.1056/NEJMra1713263. - DOI - PubMed
    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. Rodriguez L.A., Schmittdiel J.A., Liu L., Macdonald B.A., Balasubramanian S., Chai K.P., Seo S.I., Mukhtar N., Levin T.R., Saxena V. Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Netw. Open. 2024;7:e2421019. doi: 10.1001/jamanetworkopen.2024.21019. - DOI - PMC - PubMed
    1. Qin Y., Han S., Yu Y., Qi D., Ran M., Yang M., Liu Y., Li Y., Lu L., Liu Y., et al. Lenvatinib in Hepatocellular Carcinoma: Resistance Mechanisms and Strategies for Improved Efficacy. Liver Int. 2024;44:1808–1831. doi: 10.1111/liv.15953. - DOI - PubMed
    1. Forner A., Vidili G., Rengo M., Bujanda L., Ponz-Sarvisé M., Lamarca A. Clinical Presentation, Diagnosis and Staging of Cholangiocarcinoma. Liver Int. 2019;39:98–107. doi: 10.1111/liv.14086. - DOI - PubMed